On November 22, 2017 Array BioPharma Inc. (Nasdaq: ARRY) reported that its Chief Executive Officer, Ron Squarer, will present at the 2017 Piper Jaffray Healthcare Conference (Press release, Array BioPharma, NOV 22, 2017, View Source;p=RssLanding&cat=news&id=2318359 [SID1234522229]). The public is welcome to participate in the conference through a webcast on the Array BioPharma website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event:
Piper Jaffray Healthcare Conference
Presenter:
Ron Squarer, Chief Executive Officer
Date:
Wednesday, November 29, 2017
Time:
9:00 a.m. Eastern Time
Webcast:
View Source;tp_key=889917fd39

On November 22, 2017 Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, reported that Jonathan Lim, M.D., its Chairman and Chief Executive Officer, will make a presentation at the 29th Annual Piper Jaffray Healthcare Conference on November 29, 2017, at 11:00 a.m. local time (8:00 a.m. Pacific time) in New York City (Press release, Ignyta, NOV 22, 2017, View Source [SID1234522224]) .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available during the presentation in the Investors section of the company’s website at View Source, and will be archived and available at that site for 14 days.

On November 22, 2017 Bristol-Myers Squibb Company (NYSE:BMY) reported that it will take part in the Evercore ISI Biopharma Conference on Wednesday, November 29, 2017, in Boston. Fouad Namouni, senior vice president, head of Oncology Development, will answer questions about the company at 11:45 a.m. ET (Press release, Bristol-Myers Squibb, NOV 22, 2017, View Source [SID1234522221]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to a live webcast of the session at View Source Materials related to the presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be available later that day.

On November 22, 2017 SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, reported that the Company will present at the 29th Annual Piper Jaffray Healthcare Conference at the Lotte New York Palace Hotel on Tuesday, November 28, 2017 at 1:00 p.m. ET (Press release, Scynexis, NOV 22, 2017, View Source [SID1234522228]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast will be available on the investors section of the Company’s website: www.SCYNEXIS.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.

On November 22, 2017 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on Stem-to-T-Cell research, reported that that Anthony Gringeri, Ph.D., President and Chief Executive Officer, Steven Swanson, Ph.D., Senior Vice President, Research, and David Fractor, Chief Financial Officer, will present at the 10th Annual LD Micro Main Event on Thursday, December 7, 2017 at 9:30 a.m. PT (12:30 p.m. ET) in Track 3 (Press release, ImmunoCellular Therapeutics, NOV 22, 2017, View Source [SID1234522218]). The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management will be available for one-on-one meetings on Thursday, December 7, 2017. Investors interested in arranging a meeting with management should contact their LD Micro representative or Lytham Partners at (602) 889-9700 or [email protected].

Interested parties who wish to listen to the webcast of the ImmunoCellular LD Micro presentation should visit the Investor Relations section of ImmunoCellular’s website at www.imuc.com, under the Events and Presentations tab. A replay of the webcast will be available one hour after the conclusion of the event. The webcast will contain forward-looking statements. The information provided on the webcast is accurate only at the time of the webcast, and ImmunoCellular will take no responsibility for providing updated information except as required by law.